Perspective Therapeutics (CATX) executive Puhlmann received 150,000 Stock option (right to buy)
Insider transactions reported
Markus Puhlmann (Chief Medical Officer at Perspective Therapeutics Inc., CATX) reported that they received 150,000 Stock option (right to buy) on Mar 2, 2026.
- Reporting person
- Puhlmann Markus
- Role
- Chief Medical Officer
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Grant or award (A) | Stock option (right to buy)On 150,000 Common Stock1, 2 | +150,000 | - | - | 150,000 direct |
Holdings before and after
- Stock option (right to buy): 0 to 150,000 direct
Footnotes from the filing
- 1. The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the Grant Date ), and represents the Reporting Person's annual equity award for 2026.
- 2. Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Puhlmann report in this CATX Form 4?
Markus Puhlmann (Chief Medical Officer at Perspective Therapeutics Inc., CATX) reported that they received 150,000 Stock option (right to buy) on Mar 2, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for CATX
Across the 13 sessions after earlier CATX headlines, the stock closed higher 9 times and lower 3 times, with a median move of 3.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CATX | SPY |
|---|---|---|---|
| Feb 19, 2026 | Piper Sandler initiated coverage on Perspective Therapeutics with a new price target | +12.3% | -0.3% |
| Feb 17, 2026 | Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results | +3.2% | +0.2% |
| Feb 2, 2026 | Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | +33.5% | +0.5% |
| Jan 12, 2026 | Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference | -15.1% | +0.2% |
| Jan 9, 2026 | Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium | +1.1% | +0.7% |
| Dec 18, 2025 | Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | +3.1% | +0.8% |
Earlier insider filings at CATX
- Nov 17, 2025Chief Accounting Officer Hunt Jonathan Robert bought $22,295 worth of shares (11,000 units at $2.03), increasing direct ownership by 23% to 59,800 units (SEC Form 4)
- Nov 14, 2025Director Williamson Robert F Iii bought $19,946 worth of shares (9,498 units at $2.10) (SEC Form 4)
- Sep 5, 2025SEC Form 4 filed by Chief Financial Officer Sendek Joel
- Sep 5, 2025SEC Form 4 filed by Director Martinez Maria E
- Apr 1, 2025Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Follow CATX and get a push notification the moment its next story breaks.